Nasdaq

Jasper Therapeutics Reports Promising BEACON Study Results for Briquilimab in Chronic Spontaneous Urticaria Amid Drug Product Lot Investigation

Jasper Therapeutics, Inc. announced promising results from its BEACON Phase 1b/2a study of briquilimab, an antibody therapy targeting mast cell diseases like chronic spontaneous urticaria (CSU). In ...
Seeking Alpha

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
manilatimes

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage ...